Q-omics provides the consensus-scored CXCL14 profile across patient tissues and cancer cell-line models. CXCL14 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CXCL14 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, CXCL14 RNA expression shows 20,999 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, KICH, and PDAC as cancer lineages where CXCL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXCL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXCL14 survival associations across molecular data types. CXCL14 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXCL14 RNA expression–survival associations across cancer types. High CXCL14 expression shows unfavorable associations in LGG and MESO, but favorable associations in BRCA, KIRC, THCA and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CXCL14 RNA expression.
This table summarizes CXCL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CXCL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXCL14 shows lower tumor expression in KICH, LIHC and KIRP and higher tumor expression in LUAD, HNSC and LUSC. The KICH box plot shows higher CXCL14 RNA expression in normal versus tumor tissue (log2 FC = −9.112, t-test p < 0.001).
This table shows molecular features associated with CXCL14 in patient tissues and cancer cell lines. In patient samples, CXCL14 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXCL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
